FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average bu	rden							
hours ner response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Snell Kristi (Last) (First) (Middle) C/O YIELD10 BIOSCIENCE, INC. 19 PRESIDENTIAL WAY						Issuer Name and Ticker or Trading Symbol YIELD10 BIOSCIENCE, INC. [YTEN] Date of Earliest Transaction (Month/Day/Year) 02/10/2022									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below) VP Research & CSO					
(Street) WOBUR (City)		tate)	01801 (Zip)		-	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D				saction	2A. Deemed Execution Date,			Code (Instr. 5)			red (A) or 5. Amount of Securities Beneficially Owned Following			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
Common Stock 0					0/202	V2022			Code	v	Amount 6,733	(A) (D)		Price \$3.83	Transact (Instr. 3	Reported Transaction(s) (Instr. 3 and 4)		D	(Instr. 4)	
Common Stock 02/				02/10	0/202	112022					0,733			Ψ3.03	5,210 ⁽²⁾			I	By 401(k) Plan	
		-	Гable II -								osed of, convertil				Owned		,		*	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date,	4. Transa Code (i 8)				6. Date Expirati (Month/	on Dat		of Securities			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or Nur of	ount mber ares						
Stock Option (right to buy)	\$3.83	02/10/2022			A		22,500		(3)		02/10/2032	Common Stock	22,	,500	\$0	22,500	0	D		

Explanation of Responses:

- 1. The securities awarded are in the form of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 50% of the shares on 8/10/2022 and the remaining 50% on 2/10/2023.
- 2. Shares acquired as Issuer matching contributions under the Yield10 Bioscience, Inc. 401(k) Plan.
- $3. \ These options will vest and become exercisable in equal quarterly installments over 4 years from 2/10/2022, beginning on 5/10/2022 and ending on 2/10/2026.$

/s/ Megan N. Gates, attorneyin-fact

02/14/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.